Effects of Dietary α-Linolenic Acid Treatment and the Efficiency of Its Conversion to Eicosapentaenoic and Docosahexaenoic Acids in Obesity and Related Diseases

The essential fatty acid alpha-linolenic acid (ALA) is present in high amounts in oils such as flaxseed, soy, hemp, rapeseed, chia, and perilla, while stearidonic acid is abundant in echium oil. ALA is metabolized to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by desaturases and elongases in humans. The conversion of ALA to EPA and DHA is limited, and these long-chain n-3 polyunsaturated fatty acids (PUFAs) are mainly provided from dietary sources (fish and seafood). This review provides an overview of studies that explored the effects of dietary supplementation with ALA in obesity and related diseases. The obesity-associated changes of desaturase and elongase activities are summarized, as they could influence the metabolic conversion of ALA. Generally, supplementation with ALA or ALA-rich oils leads to an increase in EPA levels and has no effect on DHA or omega-3 index. According to the literature data, stearidonic acid could enhance conversion of ALA to long-chain n-3 PUFA in obesity. Recent studies confirm that EPA and DHA intake should be considered as a primary dietary treatment strategy for improving the omega-3 index in obesity and related diseases.

Automated summary

This review summarizes the effects of dietary supplementation with alpha-linolenic acid (ALA) in obesity and related diseases. It discusses the impact of obesity on desaturase and elongase activities, which may influence the metabolic conversion of ALA. Generally, supplementation with ALA or ALA-rich oils increases EPA levels and has no effect on DHA or omega-3 index. Stearidonic acid can enhance the conversion of ALA to long-chain n-3 PUFA in obesity. Recent studies suggest that EPA and DHA intake should be a primary dietary treatment strategy for improving the omega-3 index in obesity and related diseases.